GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (STU:7JN) » Definitions » Other Current Assets

Poolbeg Pharma (STU:7JN) Other Current Assets : €0.27 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma Other Current Assets?

Poolbeg Pharma's other current assets for the quarter that ended in Jun. 2024 was €0.27 Mil.

Poolbeg Pharma's quarterly other current assets increased from Jun. 2023 (€0.05 Mil) to Dec. 2023 (€0.73 Mil) but then declined from Dec. 2023 (€0.73 Mil) to Jun. 2024 (€0.27Mil).

Poolbeg Pharma's annual other current assets increased from Dec. 2021 (€0.06 Mil) to Dec. 2022 (€0.10 Mil) increased from Dec. 2022 (€0.10 Mil) to Dec. 2023 (€0.73 Mil).


Poolbeg Pharma Other Current Assets Historical Data

The historical data trend for Poolbeg Pharma's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Other Current Assets Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23
Other Current Assets
0.06 0.10 0.73

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Current Assets Get a 7-Day Free Trial 1.08 0.10 0.05 0.73 0.27

Poolbeg Pharma Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Poolbeg Pharma Other Current Assets Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines